title: Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT1- and epidermal growth factor-receptor function.
abstract: OBJECTIVE
  We previously showed that enhanced myogenic constriction (MC) of peripheral resistance arteries involves active AT(1) receptors in chronic heart failure (CHF). Recent data suggest both transactivation of EGF receptors and caveolae-like microdomains to be implicated in the activity of AT(1) receptors. Thus, we assessed their roles in increased MC in mesenteric arteries of CHF rats.
  
  
  RESULTS
  Male Wistar rats underwent myocardial infarction to induce CHF and were sacrificed after 12 weeks. The number of caveolae in smooth muscle cells (SMC) of mesenteric arteries of CHF rats was decreased by 43.6 +/- 4.0%, this was accompanied by increased MC, which was fully normalized to the level of sham by antagonists of the AT(1)-receptor (losartan) or EGF-receptor (AG1478). Acute disruption of caveolae in sham rats affected caveolae numbers and MC to a similar extent as CHF, however MC was only reversed by the antagonist of the EGF-receptor, but not by the AT(1)-receptor antagonist. Further, in sham rats, MC was increased by a sub-threshold concentration of angiotensin II and reversed by both AT(1)- as well as EGF-receptor inhibition. In contrast, increased MC by a sub-threshold concentration of EGF was only reversed by EGF receptor inhibition.
  
  
  CONCLUSIONS
  These findings provide the first evidence that decreased SMC caveolae numbers are involved in enhanced MC in small mesenteric arteries, by affecting AT(1)- and EGF-receptor function. This suggests a novel mechanism involved in increased peripheral resistance in CHF.
authors.affiliation: Department of Clinical Pharmacology, Groningen University Institute for Drug Exploration (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. y.xu@imperial.ac.uk
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.forename: Rob H
authors.initials: RH
authors.lastname: Henning
authors.forename: Maria
authors.initials: M
authors.lastname: Sandovici
authors.forename: Johannes J
authors.initials: JJ
authors.lastname: van der Want
authors.forename: Wiek H
authors.initials: WH
authors.lastname: van Gilst
authors.forename: Hendrik
authors.initials: H
authors.lastname: Buikema
mesh_terms: D000818:Animals; D021941:Caveolae / Q000648:ultrastructure*; D002452:Cell Count; D004195:Disease Models, Animal; D066246:ErbB Receptors / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006333:Heart Failure / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D007150:Immunohistochemistry; D008297:Male; D008638:Mesenteric Arteries / Q000378:metabolism / Q000503:physiopathology* / Q000648:ultrastructure; D008854:Microscopy, Electron; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000503:physiopathology* / Q000648:ultrastructure; D009200:Myocardial Contraction / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D014661:Vasoconstriction / Q000502:physiology*
chemical_list: D044140:Receptor, Angiotensin, Type 1; D066246:ErbB Receptors